Loading

Leadership
David Domzalski

David Domzalski

President and Chief Executive Officer

David Domzalski has served as our President and Chief Executive Officer and member of our board since March 2020.  Previously, since July 2017, Mr. Domzalski was Chief Executive Officer and a member of the board of Foamix Pharmaceuticals Ltd. Mr. Domzalski was with Foamix since April 2014, and previously served as President.  He has 25 years of industry experience, previously holding positions as Vice President, Sales and Marketing, at LEO Pharma Inc. from 2009 to 2013, Senior Vice President and General Manager at Azur Pharma from 2008 to 2009, and Vice President, Sales and Marketing, at Warner Chilcott from 2003 to 2008. Mr. Domzalski holds a BA in economics and political science from Muhlenberg College, Allentown, Pennsylvania.

_0010_Andrew-Saik copy

Andrew Saik

Chief Financial Officer and Treasurer

Andrew Saik has served as our Chief Financial Officer and Treasurer since March 2020.  Mr. Saik has over 20 years of accounting, finance, and general management experience at domestic and international companies. He was most recently CFO at PDS Biotechnology, Inc. (formerly Edge Therapeutics). Prior to PDS he was CFO at Vertice Pharma, LLC, a Warburg Pincus-backed company. Prior to Vertice, he was CFO at Auxilium Pharmaceuticals, Inc., where he helped lead the execution of Auxilium’s growth strategy culminating in the sale of the company for $2.6 billion at an 85% share price premium. Prior to Auxilium, he was Senior Vice President, Finance and Treasurer at Endo Health Solutions.  Prior to Endo, Mr. Saik served in senior financial management roles with increasing responsibility at Valeant Pharmaceuticals International. Mr. Saik holds a Master of Business Administration from the University of Southern California and a Bachelor of Arts from the University of California, Los Angeles.

_0003_Matthew Wiley

Matt Wiley

Chief Commercial Officer

Matt Wiley has served as our Chief Commercial Officer since March 2020.  Previously, he was Chief Commercial Officer of Foamix Pharmaceuticals Ltd. since November 2018. Mr. Wiley brings over 20 years of commercial and brand leadership experience, previously holding positions as Vice President of Marketing and Business Unit Lead at Jazz Pharmaceuticals from 2012 to 2018, as Vice President of Marketing at Azur Pharma from 2007 to 2012, and, prior to Azur, holding positions of increasing responsibility in sales, sales training, and marketing with Guilford/MGI Pharma, Salix Pharmaceuticals, Cephalon, and Rhone-Poulenc Rorer. Mr. Wiley holds a BA in english from Syracuse University.

_0005_Iain Stuart

Dr. Iain Stuart

Chief Scientific Officer

Iain Stuart, PhD, has served as our Chief Scientific Officer since March 2020.  Previously, since January 2019, he served as Chief Scientific Officer of Foamix Pharmaceuticals Ltd. Dr. Stuart was with Foamix since October 2016, and previously served as Senior Vice President of Research and Development. He has over 19 years of industry experience, previously holding various positions at LEO Pharma, Inc. from 2008 to 2016, including Director of Preclinical Development, Director of Clinical Operations, Vice President of Research and Development Project Management, and, most recently, as Vice President of Medical Strategy and Scientific Affairs. Prior to LEO Pharma, Dr. Stuart served as Senior Study Director at Inveresk Research (now Charles River), and as Project Manager, Pharmaceutical Development at Cyclacel, Inc. Dr. Stuart has a PhD and first-class honors BSc in chemistry from Glasgow Caledonian University, and was a postdoctoral fellow in medicinal chemistry at the University of Strathclyde.

_0002_Mutya Harsch

Mutya Harsch

General Counsel, Chief Legal Officer and Secretary

Mutya Harsch has served as our General Counsel, Chief Legal Officer and Secretary since March 2020.  Previously, since January 2019, she served as General Counsel and Chief Legal Officer of Foamix Pharmaceuticals Ltd. Ms. Harsch was with Foamix since January 2018, and previously served as General Counsel and Senior Vice President of Legal Affairs. She has over 19 years of legal experience, previously holding positions as Special Counsel, Mergers & Acquisitions, at Cooley LLP from 2015 to 2017, as a corporate lawyer at Davis Polk & Wardwell from 1999 to 2003 and 2005 to 2015, and as Assistant General Counsel at Warner Chilcott from 2003 to 2005. Ms. Harsch received her JD and BA from the University of California at Berkeley.

_0001_Ray Steitz

Ray Steitz

Senior Vice President, Global Human Resources

Ray Steitz has served as Senior Vice President of Global Human Resources since March 2020.  Previously, since November 2018, he served as Senior Vice President of Global Human Resources of Foamix Pharmaceuticals Ltd. Mr. Steitz has over 30 years of human resources experience, previously holding positions as Senior Vice President of Human Resources at Olam Americas Inc. from 2010 to 2018, as Global Vice President of Human Resources at Warner Chilcott from 2001 to 2010, and, prior to Warner Chilcott, holding various human resources leadership and generalist roles at Unilever. Mr. Steitz holds a BS in business from Rider University.

_0000_Russell Elliott

Dr. Russell Elliott

Senior Vice President, Pharmaceutical Development

Russell Elliott, PhD, has served as Senior Vice President of Pharmaceutical Development since March 2020.  Previously, since January 2019, Dr. Elliot served as Senior Vice President of Pharmaceutical Development of Foamix Pharmaceuticals Ltd. Dr. Elliott was with Foamix since May 2016, and previously served as Vice President of Drug Development. He has over 25 years of industry experience, previously holding positions as Head of Skincare Technology at Lonza Inc. from 2015 to 2016, Head of Product Development at Stiefel (a GSK Company) from 2011 to 2014, Head of the Center of Excellence for Liquids, Cream and Ointments at GSK (UK) from 2007 to 2011, and Principal Scientist at Procter & Gamble from 1992 to 2007. He has filed more than 60 patent applications in the area of skincare formulation. Dr. Elliott has a PhD and MA from the University of Oxford and is a Fellow of the Royal Society of Chemistry.

_0006_Deepa Desai

Deepa Desai

Vice President, Regulatory Affairs

Deepa Desai has served as Vice President of Regulatory Affairs since March 2020.  Previously, since March 2019, she served as Vice President of Regulatory Affairs of Foamix Pharmaceuticals Ltd. Ms. Desai has over 25 years of industry experience, previously holding positions as Senior Director of Regulatory Affairs at DBV Technologies from 2018 to 2019, Director of Global Regulatory Affairs at Radius Health from 2015 to 2018, Director of Regulatory Affairs at Actavis (formerly Warner Chilcott) from 2003 to 2015, and various positions in Quality Management and Regulatory Affairs at Hoffman-La Roche from 1992 to 2003. Ms. Desai holds a BA, biological sciences from Rutgers University and MS, biological sciences with a minor in business administration from Seton Hall University.

_0007_David Schuz

David Schuz

Vice President, Intellectual Property

David Schuz has served as Vice President of Intellectual Property since March 2020.  Previously, since August 2017, he served as Vice President of Intellectual Property at Foamix Pharmaceuticals Ltd. Mr. Schuz led the intellectual property function at Foamix since July 2006. Mr. Schuz has 20 years of industry experience in the field of pharmaceuticals and biotechnology intellectual property, previously holding positions at Biotechnology General Israel Ltd and Savient Pharmaceuticals, Inc. from 1999 to 2006, including Vice President from 2003 to 2006. Mr. Schuz holds an LLM from the London School of Economics, a certificate in patent law from Queen Mary London University, an M Phil (biochemistry) and a diploma of pharmacology, both from Cambridge University, and a BSc (Hons) (chemistry) from Manchester University.